170 related articles for article (PubMed ID: 34519276)
1. Serum anti-Müllerian hormone as a marker of ovarian reserve after cancer treatment and/or hematopoietic stem cell transplantation in childhood: proposal for a systematic approach to gonadal assessment.
Molinari S; Parissone F; Evasi V; De Lorenzo P; Valsecchi MG; Cesaro S; Fraschini D; Sangalli R; Cacace G; Biondi A; Balduzzi A; Cattoni A
Eur J Endocrinol; 2021 Oct; 185(5):717-728. PubMed ID: 34519276
[TBL] [Abstract][Full Text] [Related]
2. Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy.
Elchuri SV; Patterson BC; Brown M; Bedient C; Record E; Wasilewski-Masker K; Mertens AC; Meacham LR
J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):393-9. PubMed ID: 26924632
[TBL] [Abstract][Full Text] [Related]
3. The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.
Elchuri SV; Williamson RS; Clark Brown R; Haight AE; Spencer JB; Buchanan I; Hassen-Schilling L; Brown MR; Mertens AC; Meacham LR
Blood Cells Mol Dis; 2015 Jun; 55(1):56-61. PubMed ID: 25976468
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding.
Nakano H; Ashizawa M; Akahoshi Y; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2016 Jul; 104(1):110-6. PubMed ID: 27084256
[TBL] [Abstract][Full Text] [Related]
5. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies.
Jiao X; Meng T; Zhai Y; Zhao L; Luo W; Liu P; Qin Y
Front Endocrinol (Lausanne); 2021; 12():601752. PubMed ID: 33815272
[TBL] [Abstract][Full Text] [Related]
8. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
[TBL] [Abstract][Full Text] [Related]
9. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease.
George SA; Lai KW; Lewis RW; Bryson EW; Haight AE; Meacham LR
Transplant Cell Ther; 2022 Nov; 28(11):770.e1-770.e6. PubMed ID: 35995392
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Description of Gonadal Function in Sickle-cell Patients Treated With Hematopoietic Stem Cell Transplant Using Alkylator-based Conditioning Regimens.
Elchuri SV; Williamson Lewis R; Quarmyne MO; Haight AE; Cottrell HN; Meacham LR
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e575-e582. PubMed ID: 32205784
[TBL] [Abstract][Full Text] [Related]
12. Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer.
Charpentier AM; Chong AL; Gingras-Hill G; Ahmed S; Cigsar C; Gupta AA; Greenblatt E; Hodgson DC
J Cancer Surviv; 2014 Dec; 8(4):548-54. PubMed ID: 24810980
[TBL] [Abstract][Full Text] [Related]
13. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.
Visser JA; Schipper I; Laven JS; Themmen AP
Nat Rev Endocrinol; 2012 Jan; 8(6):331-41. PubMed ID: 22231848
[TBL] [Abstract][Full Text] [Related]
14. Very Low Levels of Serum Anti-Müllerian Hormone as a Possible Marker for Follicle Growth in Patients with Primary Ovarian Insufficiency Under Hormone Replacement Therapy.
Kasahara Y; Osuka S; Bayasula ; Nakanishi N; Murase T; Nakamura T; Goto M; Kotani T; Iwase A; Kikkawa F
Reprod Sci; 2021 Jan; 28(1):31-36. PubMed ID: 32737737
[TBL] [Abstract][Full Text] [Related]
15. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.
van der Kooi ALF; van Dijk M; Broer L; van den Berg MH; Laven JSE; van Leeuwen FE; Lambalk CB; Overbeek A; Loonen JJ; van der Pal HJ; Tissing WJ; Versluys B; Bresters D; Beerendonk CCM; Ronckers CR; van der Heiden-van der Loo M; Kaspers GL; de Vries ACH; Robison LL; Hudson MM; Chemaitilly W; Byrne J; Berger C; Clemens E; Dirksen U; Winther JF; Fosså SD; Grabow D; Haupt R; Kaiser M; Kepak T; Kruseova J; Modan-Moses D; Pluijm SMF; Spix C; Zolk O; Kaatsch P; Krijthe JH; Kremer LC; Yasui Y; Brooke RJ; Uitterlinden AG; van den Heuvel-Eibrink MM; van Dulmen-den Broeder E
Hum Reprod; 2021 Mar; 36(4):1120-1133. PubMed ID: 33582778
[TBL] [Abstract][Full Text] [Related]
16. Premature ovarian insufficiency and early depletion of the ovarian reserve in the monogenic Mulibrey nanism disorder.
Karlberg S; Tiitinen A; Alfthan H; Lipsanen-Nyman M
Hum Reprod; 2018 Jul; 33(7):1254-1261. PubMed ID: 29860321
[TBL] [Abstract][Full Text] [Related]
17. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
Transplant Cell Ther; 2023 Aug; 29(8):531.e1-531.e4. PubMed ID: 37169288
[TBL] [Abstract][Full Text] [Related]
18. Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment.
Nyström A; Mörse H; Nordlöf H; Wiebe K; Artman M; Øra I; Giwercman A; Henic E; Elfving M
Acta Oncol; 2019 Feb; 58(2):218-224. PubMed ID: 30558460
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation.
Bender JD; Oquendo-Del Toro H; Benoit J; Howell JC; Badia P; Davies SM; Grimley MS; Jodele S; Phillips C; Burns K; Marsh R; Nelson A; Wallace G; Dandoy CE; Pate A; Strine AC; Frias O; Breech L; Rose SR; Hoefgen H; Khandelwal P; Myers KC
Transplant Cell Ther; 2023 Feb; 29(2):130.e1-130.e8. PubMed ID: 36323400
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
